Jordan E. Tuia

Dec 11, 2023 | jamanetwork.com | Milos D. Miljkovic |Miloš Miljković |Jordan E. Tuia

Key PointsQuestion  Is the median annual cost of cancer drugs associated with the novelty of cancer drugs approved in the US over a 6-year period? Findings  In this cross-sectional study, between January 1, 2015, and December 31, 2020, there were 224 cancer drug approvals across 119 individual drugs. The median annual cost was $196 000, and there was no significant difference in cost between first-in-class, next-in-class, and subsequent approvals of an already approved drug.

Dec 11, 2023 | jamanetwork.com | Milos D. Miljkovic |Miloš Miljković |Jordan E. Tuia

Key PointsQuestion  Is the median annual cost of cancer drugs associated with the novelty of cancer drugs approved in the US over a 6-year period? Findings  In this cross-sectional study, between January 1, 2015, and December 31, 2020, there were 224 cancer drug approvals across 119 individual drugs. The median annual cost was $196 000, and there was no significant difference in cost between first-in-class, next-in-class, and subsequent approvals of an already approved drug.

Oct 26, 2023 | jamanetwork.com | Timothée Olivier |Alyson Haslam |Jordan E. Tuia

Key PointsQuestion  Is availability of therapeutics for patients with specific human leukocyte antigen (HLA) subtypes associated with inequalities by race and ethnicity?

Jul 14, 2023 | medrxiv.org | Sarah Miller |Jordan E. Tuia |Vinay Prasad

Disclosure: Vinay Prasad′s Disclosures. (Research funding) Arnold Ventures (Royalties) Johns Hopkins Press, Medscape, and MedPage (Honoraria) Grand Rounds/lectures from universities, medical centers, non–profits, and professional societies. (Consulting) UnitedHealthcare and OptumRX. (Other) Plenary Session podcast has Patreon backers, YouTube, and Substack. All other authors have no financial nor non–financial conflicts of interest to report. None.